JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
2025 · iScience · 4 citations
https://doi.org/10.1016/j.isci.2025.111876
M
Marjolein van Heerden
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
60
Papers
1.1K
Citations
19
h-index
23
i10-index
Marjolein van Heerden is an academic researcher from Johnson & Johnson (United States). The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & COVID-19 Clinical Research Studies & Advancements in Transdermal Drug Delivery. The author has an h-index of 19, co-authored 51 publications.
ORCID: 0000-0002-0852-092XPapers by this author
worksCharacteristics of heart failure with a preserved ejection fraction in black South African patients
2024 · IJC Heart & Vasculature · 3 citations
https://doi.org/10.1016/j.ijcha.2024.101408
European Society of Toxicologic Pathology—Pathology 2.0 Mass Spectrometry Imaging Special Interest Group: Mass Spectrometry Imaging in Diagnostic and Toxicologic Pathology for Label-Free Detection of Molecules—From Basics to Practical Applications
2025 · Toxicologic Pathology · 2 citations
https://doi.org/10.1177/01926233241311269
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat